Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06428838
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-24
First Post:
2024-05-16
Brief Title:
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
Sponsor:
Dr George Medvedev
Organization:
HealthTech Connex Inc
Study Overview
Official Title:
Eptinezumab as an Adjunct to Standard of Care for MIGRANE in an Acute EmeRgency Context Migraine ERase Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to investigate how a medication called eptinezumab Vyepti given to patients in the Emergency Department ED might help prevent migraines from happening again The results of this study may help inform better ways to manage patients with migraines in the ED
Eptinezumab is currently approved by Health Canada for the preventive treatment of migraine but its short-term effectiveness in the ED context is unknown Unlike other migraine treatments used in the ED eptinezumab can rapidly interrupt the migraine process potentially also preventing migraine from coming back in the short term
Most patients with a diagnosis of migraine have no access to preventative therapies This study will be able to provide access to preventative therapy at the earliest stages of a migraine attack Administering this medication in the ED may stop the attack more effectively compared to current therapies
This study wants to see if eptinezumab could help stop migraines from coming back after individuals have been treated in the ED The study will also explore whether eptinezumab could reduce how often individuals with migraine might need to come back to the ED what other medications they might need alongside eptinezumab and how they feel overall
Eptinezumab is currently approved by Health Canada for the preventive treatment of migraine but its short-term effectiveness in the ED context is unknown Unlike other migraine treatments used in the ED eptinezumab can rapidly interrupt the migraine process potentially also preventing migraine from coming back in the short term
Most patients with a diagnosis of migraine have no access to preventative therapies This study will be able to provide access to preventative therapy at the earliest stages of a migraine attack Administering this medication in the ED may stop the attack more effectively compared to current therapies
This study wants to see if eptinezumab could help stop migraines from coming back after individuals have been treated in the ED The study will also explore whether eptinezumab could reduce how often individuals with migraine might need to come back to the ED what other medications they might need alongside eptinezumab and how they feel overall
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None